Healthcare Lobbying, Medicare, and Medicaid Policy in the U.S.
This paper examines three interconnected dimensions of the U.S. healthcare system. First, it analyzes the influence of major healthcare lobbying groups — PhRMA, the American Medical Association, and the American Physical Therapy Association — on legislation, drug pricing, and access to care. Second, it considers the relationship between population health and economic performance, with particular attention to the scope, eligibility, and limitations of Medicare and Medicaid. Third, it compares U.S. health expenditure and outcomes against other OECD nations, finding that higher spending does not translate into better results, and concludes with policy recommendations for restructuring Medicare to address cost growth and the demands of an aging population.
- Healthcare Lobbying Groups and Their Impact: PhRMA, AMA, and APTA lobbying effects on patients
- Population Health and Economic Performance: Health outcomes linked to GDP and economic productivity
- Medicare and Medicaid: Coverage and Eligibility: Scope, eligibility rules, and critiques of both programs
- U.S. Health Spending in Global Perspective: U.S. outspends peers but underperforms on outcomes
- Medicare Reform Recommendations: Proposed cost-containment adjustments to Medicare
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper integrates multiple credible sources — government agencies, peer-reviewed research, and policy commentary — to support each distinct discussion point.
- It balances objective description with a clearly stated first-person policy perspective, especially in the Medicare reform section, without abandoning evidence-based reasoning.
- The three-part structure is logically sequenced: from micro-level industry lobbying, to macro-level economic impacts, to a comparative global lens — creating a coherent analytical arc.
Key academic technique demonstrated
The paper demonstrates comparative policy analysis: it consistently measures U.S. healthcare institutions and outcomes against external benchmarks — whether other OECD nations or alternative legislative approaches — to construct a critical evaluation. This technique helps readers see not just what U.S. policy does, but what it fails to achieve relative to realistic alternatives.
Structure breakdown
The paper is organized into three discussion sections. The first addresses lobbying groups and their dual role as both promoters of professional interests and obstacles to broader public health goals. The second explores the health-GDP relationship and outlines Medicare and Medicaid's eligibility criteria and limitations. The third compares U.S. health spending to peer nations and proposes Medicare cost-containment reforms. A consolidated reference list follows all three sections.
Healthcare Lobbying Groups and Their Impact
Multiple healthcare lobbyist groups operate within the United States. To a large extent, these groups engage in advocacy efforts to collectively or individually influence decision-making and public policy. Three major groups considered here are the Pharmaceutical Research & Manufacturers of America (PhRMA), the American Medical Association (AMA), and the American Physical Therapy Association (APTA). It is worth noting that these lobbyists can be both beneficial and detrimental to healthcare. On the positive side, they support the professional advancement of their members. For instance, the American Medical Association is actively involved in advancing public health through directed efforts to eliminate obstacles that impede the delivery of competent patient care (American Medical Association, 2021). However, in seeking to advance the interests of their members, some healthcare lobbyist groups can also work against the general health and wellbeing of patients.
When it comes to PhRMA, this lobby group concerns itself with advancing the interests of enterprises operating in the U.S. pharmaceutical industry. Through PhRMA's lobbying efforts, consumers are likely to continue paying higher prices for drugs that might otherwise be cheaper. As Anderson (2020) points out, in 2019, Congress's failure to pass any legislation with a beneficial impact on drug prices could be attributed directly to PhRMA's lobbying activities. Similarly, the AMA's dedicated efforts to block progress toward universal health coverage mean that many Americans are likely to continue lacking access to comprehensive coverage — as Michels, Cox, Siddula, and Tai (2019) observe. On the other hand, the American Physical Therapy Association has been at the forefront of lobbying federal agencies and Congress to implement measures that improve access to physical therapist services, which is likely to result in better quality of care for patients.
Population Health and Economic Performance
The health of a population has a significant impact on the economy. Studies have demonstrated that "improvements in health can lead to an increase in Gross Domestic Product (GDP) and vice versa" (Rughupathi & Rughupathi, 2020, p. 37). It follows that population health has a positive impact on GDP, which can be attributed to decreased absenteeism rates, reduced productivity losses caused by worker illness, and a nation's ability to direct more resources toward developmental undertakings rather than escalating healthcare costs. To ensure that the economy is not impacted negatively, governments must put in place policies that secure the health and wellbeing of citizens. This can be accomplished through public education on strategies for improved health and wellbeing, as well as through the adoption of universal coverage frameworks.
References
American Medical Association. (2021). About. https://www.ama-assn.org/about
Anderson, M. (2020). PhRMA spent a record $29M on lobbying in 2019. Becker's Hospital Review.
Feyman, Y. (2017). How to save and fix Medicare. National Affairs.
Michels, J., Cox, W., Siddula, A., & Tai, R. (2019). Why we're fighting the American Medical Association. The Guardian. https://www.theguardian.com/commentisfree/2019/jun/06/why-were-fighting-the-american-medical-association
Rasmussen, B. (2021). What are the advantages and disadvantages of Medicare Advantage plans? Health.
Rughupathi, V., & Rughupathi, W. (2020). Healthcare expenditure and economic performance: Insights from the United States data. Front Public Health, 8(2), 34–41.
Tikkanen, R., & Abrams, M. K. (2020). U.S. health care from a global perspective, 2019: Higher spending, worse outcomes? Commonwealth Fund.
U.S. Department of Health and Human Services. (2021). Who is eligible for Medicaid?
U.S. Department of Health and Human Services. (2021). Who is eligible for Medicare?
Create your account
Always verify citation format against your institution’s current style guide requirements.